Theolytics

Executive Summary

Theolytics is a UK-based biotechnology company pioneering oncolytic immunotherapy to overcome the barriers in treating solid tumors. Founded in 2017 and headquartered in Oxford, the company leverages a proprietary platform to engineer viruses that selectively infect and destroy cancer cells while stimulating an immune response. Their approach aims to address the immunosuppressive tumor microenvironment, with a focus on improving patient outcomes in difficult-to-treat cancers. Despite operating in a competitive space, Theolytics differentiates itself through a unique viral engineering strategy that enhances tumor penetration and immune activation. The company is privately held and has not disclosed funding details, suggesting it may be in early development or operating with limited public visibility. Given the growing interest in oncolytic viruses and the urgent need for effective solid tumor therapies, Theolytics represents a promising but early-stage opportunity in the oncology space.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial40% success
• H1 2026Announcement of Series A or B Funding Round50% success
• Q2 2026Presentation of Preclinical Data at Major Conference70% success